pure autonomic failure

a degenerative, sporadic neurologic disorder of adult onset, manifested principally as orthostatic hypotension and syncope, with no neurologic defects other than autonomic nervous system dysfunction evident; probably caused by selective degeneration of neurons in the sympathetic ganglia, with denervation of smooth muscle vasculature and the adrenal glands.

Synonym(s): Bradbury-Eggleston syndrome

pure autonomic failure

Neurology A sporadic, idiopathic cause of persistent orthostatic hypotensio in and other manifestations of autonomic failure, unaccompanied by other neurologic features

pure au·to·nom·ic fail·ure

(pyūr aw'tō-nom'ik fāl'yŭr)

A degenerative, sporadic neurologic disorder of adult onset, manifested principally as orthostatic hypotension and syncope, with no neurologic defects other than autonomic nervous system dysfunction evident; probably caused by selective degeneration of neurons in the sympathetic ganglia, with denervation of smooth muscle vasculature and the suprarenal glands.
Synonym(s): Bradbury-Eggleston syndrome.

Mentioned in ?

Bradbury-Eggleston syndrome

References in periodicals archive ?

TABLE Conditions associated with autonomic dysfunction (1) * Alcoholism/alcoholic neuropathy * Amyloidosis * Botulism * Cerebral infarcts * Diabetes mellitus * Guillain-Barre syndrome * Huntington's disease * Multiple sclerosis * Multiple systems atrophy * Parkinson's disease * Porphyria * Postural orthostatic tachycardia syndrome * Primary hyperhidrosis * Pure autonomic failure * Reflex sympathetic dystrophy * Spinal cord lesions * Toxic neuropathies * Tumors, paraneoplastic neuropathies

Autonomic dysfunction: a guide for FPs

Elam et al., "Autonomic innervation in multiple system atrophy and pure autonomic failure," Journal of Neurology, Neurosurgery & Psychiatry, vol.

Should Skin Biopsies Be Performed in Patients Suspected of Having Parkinson's Disease?

[3] Nonstandard abbreviations: L-DOPS, L-threo-3,4-dihydroxyphenylserine; NE, norepinephrine; DOPAL, dihydroxyphenylacetaldehyde; PAD, pure autonomic failure; MSA, multiple system atrophy; DOPA, dihydroxyphenylalanine; NMR, nuclear magnetic resonance; LC-ED, liquid chromatography with electrochemical detection; IV, intravenous.

Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde

Northera is an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.

FDA Advisory Committee to review Chelsea Therapeutics' Northera NDA on 23 Feb

Food and Drug Administration (FDA) has granted Orphan Drug designation to its drug candidate Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with Primary Autonomic Failure, a group of diseases that includes Parkinson's Disease, Pure Autonomic Failure (PAF) and Multiple Systems Atrophy (MSA).

FDA GRANTS ORPHAN DRUG DESIGNATION FOR DROXIDOPA

Migraine shares significant diagnostic and clinical features with both pure autonomic failure and multiple system atrophy, yet represents a distinct subtype of chronic sympathetic dysfunction.

A study of autonomic functions in the patients of episodic migraine

29 September 2011 - US Chelsea Therapeutics International Ltd (NASDAQ:CHTP) announced today that it had submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval to market Northera (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with Parkinson's disease, multiple system atrophy and pure autonomic failure, dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy.